Picture of Zynerba Pharmaceuticals logo

ZYNE — Zynerba Pharmaceuticals News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall Cap

Zynerba Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

* Zynerba Pharmaceuticals Inc  ZYNE.OQ  reported a quarterly
adjusted loss of 25 cents​​ per share for the quarter ended in
June. The mean expectation of seven analysts for the quarter was
for a loss of 24 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Zynerba Pharmaceuticals Inc's reported EPS for the quarter was
a loss of 25 cents​.
* The mean earnings estimate of analysts had risen by about 1.8%
in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Zynerba Pharmaceuticals Inc shares had fallen by 16.1% this
quarter and gained 34.5% so far this year.
* The company reported a quarterly loss of $9.95 million.
* Wall Street's median 12-month price target for Zynerba
Pharmaceuticals Inc is $8.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
This summary was machine generated August 9 at 11:47 a.m.  ​All
figures in US dollars unless otherwise stated

Recent news on Zynerba Pharmaceuticals

See all news